Valuation: Syntara Limited

Market Cap 45.12M 31.36M 27.48M 25.33M 23.39M 44.36M 2.99B 303M 119M 1.47B 118M 115M 5.07B P/E 2026 *
-3.83x
P/E 2027 * -4.6x
Enterprise Value 34.12M 23.72M 20.78M 19.16M 17.69M 33.55M 2.26B 229M 89.85M 1.12B 89.04M 87.1M 3.84B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
87.28%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Syntara Limited

Current month+15.00%
1 month-8.00%
3 months-31.34%
6 months-30.30%
Current year-34.29%
1 week 0.02
Extreme 0.02
0.02
1 month 0.02
Extreme 0.019
0.02
Current year 0.02
Extreme 0.019
0.04
1 year 0.02
Extreme 0.019
0.07
3 years 0.01
Extreme 0.014
0.1
5 years 0.01
Extreme 0.014
0.15
10 years 0.01
Extreme 0.014
0.37
Manager TitleAgeSince
Chief Executive Officer 64 2013-03-11
Director of Finance/CFO - 2024-08-30
Chief Tech/Sci/R&D Officer - 2022-06-30
Director TitleAgeSince
Director/Board Member 64 2013-03-11
Chairman 68 2023-10-02
Director/Board Member - 2022-12-15
Date Insider Type Main position Quantity % Market Cap.
25-03-12Buy

Director

9,753,442 0.6008%
24-09-23Buy

Director

53,571,429 4.1513%
21-08-11Expiration

Chief Executive Officer

471,000 0.1040%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-53.06%-55.77% 31.33M
-4.14%-8.06%+57.35%+117.24% 56.98B
+1.84%-0.66%+75.79%+93.87% 53.58B
-2.24%+3.59%+19.60%+466.72% 25.63B
-1.60%-6.21%-19.69%-14.84% 23.51B
+2.43%+1.06%+47.70%-0.11% 19.43B
-3.19%0.00%+33.99%-26.87% 18.12B
-6.84%+2.18%+195.12%+357.18% 16.46B
+8.74%+3.51%+53.81% - 14.13B
-1.05%+1.16%+25.08%+196.28% 14.35B
Average -0.60%+0.63%+43.57%+125.97% 24.22B
Weighted average by Cap. -1.02%+0.29%+54.66%+138.22%

Financials

2026 *2027 *
Net sales - -
Net income -13.1M -9.1M -7.98M -7.35M -6.79M -12.88M -868M -87.93M -34.49M -428M -34.18M -33.44M -1.47B -32.1M -22.31M -19.55M -18.02M -16.64M -31.56M -2.13B -215M -84.52M -1.05B -83.76M -81.94M -3.61B
Net Debt -11M -7.64M -6.7M -6.18M -5.7M -10.81M -729M -73.84M -28.96M -359M -28.7M -28.08M -1.24B -30.4M -21.13M -18.51M -17.07M -15.76M -29.89M -2.01B -204M -80.04M -993M -79.32M -77.6M -3.42B
Logo Syntara Limited
Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing topical pan-LOX inhibitors in scar revision, keloid scarring and scar prevention post-surgery. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.
Employees
-
Date Price Change Volume
26-07-10 A$0.0230 0.00% 2,628,315
26-07-09 A$0.0230 0.00% 1,165,657
26-07-08 A$0.0230 +4.55% 1,262,913
26-07-07 A$0.0220 -8.33% 8,642,153
26-07-06 A$0.0240 +4.35% 5,509,916
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0230AUD
Average target price
0.1050AUD
Spread / Average Target
+356.52%

Quarterly revenue - Rate of surprise